"Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information ...

Sangamo Therapeutics said on Monday it would regain the rights to its hemophilia A gene therapy following the termination of a co-development agreement with partner Pfizer, sending its shares down 30.

Shares of Pfizer Inc. PFE shed 0.75% to $26.42 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 1.07% to 5,906.94 and Dow Jones ...

A judge who is married to a former Pfizer executive is overseeing Mangione’s federal pretrial hearings. But she won’t oversee ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement.

Why Kirk Spano sees Pfizer as one of the next big winners from AI and why he thinks investors should be selling cash secured ...

A new study published in the British Medical Journal (BMJ) has identified a link between the contraceptive injection ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...